(Q41721378)

8 October 2017

title

Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension (English)

1 reference

8 October 2017

1 reference

Lee DA

1

1 reference

8 October 2017

publication date

1 January 2000

1 reference

8 October 2017

published in

Clinical Therapeutics

1 reference

8 October 2017

volume

22

1 reference

8 October 2017

issue

1

1 reference

8 October 2017

page(s)

53-65

1 reference

Changing therapeutic paradigms in glaucoma management

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987977-1

7 January 2021

Effects of brimonidine on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987977-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987977-1

1 reference

7 January 2021

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987977-1

7 January 2021

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987977-1

7 January 2021

Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987977-1

7 January 2021

The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987977-1

7 January 2021

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987977-1

7 January 2021

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987977-1

7 January 2021

10.1016/S0149-2918(00)87977-1

Identifiers

DOI

1 reference

8 October 2017

1 reference